

UBS Floating Rate Income Bond Fund USD K-B-acc

Fund Fact Sheet

UBS Bond Funds > UBS High Yield Funds

Fund description

 The actively managed fund invests globally across sectors, mainly in floating rate, high yield corporate and securitized bonds denominated in various currencies.

Please see additional information on the following page. 2.


Name of fund	HRS (Luv) R	ond SICAV - Floating Rate
ivaille Of Tuffu	ODS (LUX) D	Income (USD)
Claura alara	LIDC /L\ D= = -l CI	• • •
Share class	OR2 (Frix) Roud 21	CAV - Floating Rate Income
		(USD) K-B-acc
ISIN		LU2404247624
Securities no.		114 511 619
Bloomberg ticke	r	UBRIUKB LX
Currency of fund	d / share class	USD/USD
Launch date		10.11.2021
Issue/redemption	า	daily
Swing pricing		yes
Accounting year	end	31 May
Benchmark	No representative	reference index is available
Theoretical yield	to maturity (gross)1	6.94%
Theoretical yield	to worst (net)2	6.11%
Option Adjusted	Duration	0.24
Distribution		Reinvestment
Management fe	e p.a.	0.00%
Ongoing costs p	.a. ³	0.16%
Average rating		BB3
Name of the Ma	nagement	UBS Asset Management
Company		(Europe) S.A., Luxembourg
Fund domicile		Luxembourg
SFDR Alignment		Art.6
4 3 6 1 1 1 1 1 2 1 2	1 6 6 111 1	11 - 11 - 1 - 1 - 1 - 1 - 1

Yield to maturity is before fees. It is not a distributed yield nor reflects anticipated income to be earned by the fund. It may include the effect of some derivatives, including swaps and FX forwards, which can form a significant part of the investment strategy but do not pay a regular income. It is in the base currency of the master fund and not specific to a share class.

Fund Statistics

Net asset value (USD, 29.11.2024)	128.16
Last 12 months (USD) – high	128.51
- low	114.52
Total fund assets (USD m) (29.11.2024)	264.94
Share class assets (USD m)	10.48

Performance (basis USD, net of fees)¹



Fund performance net of fees (left-hand scale) Fund performance per year in % net of fees (right-hand scale)

Past performance is not a reliable indicator of future results.

in %	2021	2022	2023	2024	Nov.	LTD3	Ø p.a.	Ø p.a.
				YTD ²	2024	:	3 years	5 years
Fund (USD)	n.a.	1.20	14.97	9.83	0.98	28.16	8.98	n.a.

The performance shown does not take account of any commissions, entry or exit charges.

- These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.

 YTD: year-to-date (since beginning of the year)
- 3 LTD: launch-to-date

in %	06.2024	07.2024	08.2024	09.2024	10.2024	11.2024
Fund (USD)	0.54	1.09	0.61	0.75	0.83	0.98

Key Figures

	2 years	3 years	5 years
Volatility ¹			
– Fund	2.33%	3.98%	n.a.
Sharpe ratio	3.14	1.26	n.a.
Risk free rate	5.18%	3.95%	n.a.

¹ Annualised standard deviation

For more information

UBS Fund Infoline: 0800 899 899 Internet: www.ubs.com/funds Contact your client advisor

Portfolio management representatives

Matthew lannucci Branimir Petranovic Robert Martin

 ² This does not constitute a guarantee by UBS Asset Management.
 3 As at 18.11.2024, without transaction costs

UBS Floating Rate Income Bond Fund USD K-B-acc

Credit quality (%)

	Fund	
BBB	■ 3.5	
BB	24.6	
В		58.2
CCC	4.3	
Cash & Equivalents	7.5	
Not rated	■ 2.0	

Investment instrument exposure (%)

	Fund
Floating Rate Note	61.7
Physical Floating Rate Notes	29.9
Cash & Equivalents	7.5
Credit Derivatives	0.9

Benefits

Investors gain access to a globally diversified portfolio with reduced interest rate risk and attractive income potential as the key objective.

Additional information

- The portfolio management team combines different bond instruments in line with their investment views with the aim to reduce interest rate risk, enhance income potential, diversify credit risk and manage liquidity.
- At fund level, any non-USD currency exposure is hedged back to USD.
- This fund is not managed in reference to any benchmark.

5 largest positions (%)

	Fund
Teva Pharmaceutical Industries Ltd	2.8
Nidda Healthcare Holding	2.4
Cirsa Finance International	2.4
Galaxy	1.8
Xerox Holdings Corp	1.7

Sector exposure (%)

beeter experie (70)		
	Fund	
Industrials	69.4	
Financials	16.5	
Cash & Equivalents	7.5	
Utility	■ 1.7	
Interest Rate Derivatives Related	0.9	
Securitized	0.4	
Quasi Government	0.4	
Others	■ 3.2	

Risks

The fund's net asset value depends on interest rate and credit spread movements and will be negatively affected should any issuer held in the portfolio default. Depending on the credit quality, default risk is higher with high yield bonds than with investment grade corporate and government bonds. The fund may use derivatives, which involve counterparty risk and higher loss risk versus security investments as the option, future and swap markets are volatile. The fund may invest in emerging markets, which are at an early stage of development and typically involve high price volatility, lower market transparency, regulatory hurdles, corporate governance, political and social challenges, etc. All investments are subject to market fluctuations. Every fund has specific risks, which may increase considerably in unusual market conditions. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. **Switzerland**: Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossarv

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved